The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations.
 
Daneng Li
Consulting or Advisory Role - Abbvie; AstraZeneca; Delcath Systems; Eisai; Exelixis; Genentech; Merck; Sumitomo Pharma Oncology; Tersera; TransThera Biosciences; TriSalus Life Sciences
Speakers' Bureau - Eisai; Exelixis; Ipsen; SERVIER; Tersera
Research Funding - AstraZeneca (Inst)
 
Eric Xueyu Chen
Honoraria - AstraZeneca Canada; Bayer; Eisai; GlaxoSmithKline; Ipsen; Merck; Pfizer; Roche
Research Funding - 1Globe Health Institute; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Nubiyota; Repare Therapeutics; Roche Canada
 
Zishuo Ian Hu
No Relationships to Disclose
 
David Hsieh
No Relationships to Disclose
 
Jimmy J. Hwang
Consulting or Advisory Role - AstraZeneca; Caris Centers of Excellence; Ipsen
Research Funding - Boehringer Ingelheim (Inst); Caris Centers of Excellence (Inst)
 
Lynn G. Feun
Research Funding - Merck Sharp & Dohme (Inst)
 
Joseph Wang Franses
Consulting or Advisory Role - Eisai; Foundation Medicine; Genentech; SERVIER
Research Funding - Bristol Myers Squibb Foundation (Inst); Eisai (Inst); Genentech/Roche (Inst)
 
Gentry Teng King
Consulting or Advisory Role - Novartis; Pfizer; QED Therapeutics; Tempus; Zymeworks
Research Funding - Bayer (Inst)
 
Thomas Drake
Research Funding - Iterion Therapeutics (Inst); Iterion Therapeutics (Inst)
 
Toshiyasu Suzuki
Research Funding - Iterion Therapeutics (Inst)
 
Thomas G Bird
Research Funding - Iterion Therapeutics
 
Stephen Horrigan
Employment - Iterion Therapeutics
Leadership - Iterion Therapeutics
Stock and Other Ownership Interests - Iterion Therapeutics
Consulting or Advisory Role - HBV tech Inc.; Salarius Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Iterion Therapeutics
Travel, Accommodations, Expenses - Iterion Therapeutics
 
Jean Chang
Employment - Iterion Therapeutics
Leadership - Iterion Therapeutics
Stock and Other Ownership Interests - Iterion Therapeutics
 
David D. Stenehjem
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Aprea Therapeutics; Bristol-Myers Squibb; Dracen Therapeutics; Iterion Therapeutics; Mirati Therapeutics; Molecular Templates; Salarius Pharmaceuticals; SonaCare Medical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GRAIL (Inst); Novartis (Inst); SpringWorks Therapeutics (Inst)
 
Casey Cunningham
Employment - Iterion Therapeutics
Leadership - Geneos; Iterion Therapeutics; MycRx
Stock and Other Ownership Interests - Iterion Therapeutics
Travel, Accommodations, Expenses - Iterion Therapeutics